Upadacitinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Upadacitinib and local guidelines before prescribing.

JAK inhibitor

Mechanism

JAK1 inhibitor.

Uses

Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn disease, atopic dermatitis.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Infections, herpes zoster, raised lipids, cytopenias, VTE, MACE.

Interactions

CYP3A4 inhibitors and inducers.

Contraindications and cautions

Active infection, severe liver impairment

Monitoring

FBC, LFT, lipids

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Avoid in severe liver impairment

Overdose and reversal

Supportive

Special advice

Same MHRA JAK caution groups; screen for TB and hepatitis.

More from the textbook: uses, cautions and other points
Where it is discussed in the book